GLP1R and acute respiratory distress syndrome: Haryanto et al. (2021) found that the use of GLP1-RA (liraglutide) was capable of stimulating the expression of pulmonary ACE2 [42,45], mainly expressed in alveolar epithelial cells, enterocytes, and blood vessels [42] upstream of the counter-regulatory RAS pathway [42], which exerts a negative effect on inflammatory and fibrotic processes [44] and can slow down the progression of acute respiratory distress syndrome (ARDS) [42,45], including the one caused by the SARS-CoV-2 infection [45].